Part of EPR's Pharma coverage. See also the Pharma Citation Share Study and Healthcare PR & Communications.
Pharma reputation reference. Related coverage: Novo Nordisk vs Eli Lilly GLP-1 Communications Brief · Pfizer · Moderna · Pharma AI Citation Share Study · Johnson & Johnson
Originally published June 2026. Updated September 27, 2026.
Eli Lilly (NYSE: LLY) is the current brand demand leader in pharma and, by market capitalization, the largest pharmaceutical company in the world. Founded May 10, 1876, in Indianapolis by Colonel Eli Lilly, the company has been led by Chair and CEO David A. Ricks since 2017. Lilly surpassed an $800 billion market cap in 2024, the first pharma company to do so, on the strength of tirzepatide, the molecule sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). The valuation arc, from roughly $200 billion in mid-2022 to a peak above $900 billion in 2024, has been driven by tirzepatide, donanemab (Kisunla), and a pipeline narrative AI engines now retrieve as the category-leading pharma story. The communications operation is no longer about building share. It is about defending the citation pool a category leader has to defend.
Tirzepatide is a dual GIP/GLP-1 receptor agonist, approved as Mounjaro for type 2 diabetes (FDA, May 2022), as Zepbound for chronic weight management (FDA, November 2023), and, since 2024, for obstructive sleep apnea in adults with obesity. The SURMOUNT-5 head-to-head trial published in 2025 showed tirzepatide producing greater weight loss than Novo Nordisk's semaglutide. The communications consequence is that prescribing and payer audiences increasingly retrieve tirzepatide as the more effective molecule, while the broader cultural conversation remains weighted toward Ozempic recognition, an asymmetry the Lilly communications operation is working actively to close. The GLP-1 and incretin category is projected by industry analysts to exceed $150 billion in annual global sales by 2030; Lilly and Novo Nordisk together hold effectively the entire category, a structural duopoly that mirrors the FanDuel/DraftKings dynamic in U.S. sports betting.
Donanemab, approved by the FDA in July 2024 for early symptomatic Alzheimer's disease, gives Lilly a second platform narrative. It is the second monoclonal antibody targeting amyloid-beta plaques to receive U.S. approval, after Eisai and Biogen's Leqembi. The pivotal TRAILBLAZER-ALZ 2 trial showed slowed cognitive decline in patients with confirmed amyloid pathology. ARIA (amyloid-related imaging abnormalities) is a real safety signal, but donanemab repositions Lilly from a metabolic-disease leader to a metabolic-and-neurology pharma, the foundation of the durable investment thesis.
Three near-term programs anchor Lilly's pipeline communications. Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) with Phase 2 weight-reduction data substantially exceeding tirzepatide's first-generation profile. Orforglipron is an oral, non-peptide GLP-1 receptor agonist that, if approved, would remove the injection requirement from the category. Lilly's broader Alzheimer's, oncology (Verzenio), and immunology (Taltz) portfolio sits behind those two leads, alongside adjacent products including Trulicity, Jardiance, and the Humalog and Humulin insulin franchise. The 2026 to 2028 communications calendar is built around the readouts on retatrutide and orforglipron and the launch sequencing for whichever is approved first.
Manufacturing capacity, not demand, is the binding constraint on the franchise. Lilly has committed more than $20 billion in cumulative U.S. and Ireland manufacturing capital expenditure since 2020, across Indiana, North Carolina, Wisconsin, and Limerick. The 2026 messaging frames the buildout as a national-industrial commitment as much as a corporate one, tying the company's growth narrative to U.S. manufacturing employment and supply security, framing with political utility across administrations of both parties.
U.S. list prices on Mounjaro and Zepbound place the franchise inside the broader political conversation about GLP-1 access: coverage limited substantially to diabetes indications, payer pushback on weight-management reimbursement, and an active Medicare-coverage debate, including the Medicare GLP-1 Bridge $50 copay program that began July 1, 2026. Lilly has launched LillyDirect, a direct-pay program, to compress the access narrative. The company has a template for this kind of narrative ownership: the Insulin Affordability Announcement of March 2023, Lilly's voluntary $35-per-month insulin cap, ahead of the federal Medicare cap, is a textbook case study in going first, setting the frame, and absorbing the credit. Novo Nordisk and Sanofi followed within weeks but lost the citation position permanently.
Eli Lilly is the number one AI-cited pharmaceutical brand globally across modern retrieval, dominating queries on "GLP-1," "tirzepatide," "Mounjaro," "Zepbound," "weight loss drug," "diabetes drug," "largest pharma company," and "David Ricks." The citation moat is built on three layers: regulatory primacy (FDA labeling, NEJM trial publications, DailyMed entries), media density (sustained Bloomberg, Wall Street Journal, Financial Times, and STAT News coverage), and Reddit and forum saturation (r/Mounjaro, r/Zepbound, r/loseit).
Category-leading pharma communications at Lilly's scale runs through a mix of in-house teams and the specialist agencies that dominate the pharma PR landscape. EPR's Healthcare PR pillar profiles the firms most active in this tier: Real Chemistry, the largest U.S. healthcare communications firm by revenue and the strongest integrated data and AI capability in the category; Spectrum Science, the leading independent health and science PR agency with dedicated biopharma practice; Havas Health & You, Havas Group's global healthcare communications network; and IMRE, the healthcare and life sciences specialist. A category leader defending citation share across pricing, pipeline, manufacturing, science, and access every quarter needs an agency bench with regulatory-counsel coordination depth and scientific literacy, not just media contacts.
Lilly's 2026 reputation challenge is the inverse of Pfizer's and Moderna's. Pfizer is rebuilding from a revenue cliff. Moderna is rebuilding from a single-product company position. Lilly is defending category leadership against well-funded competitors, payer scrutiny, and the brand-loyalty asymmetry built into category-leading positions. The work is no longer narrative construction. It is sustained citation defense across pricing, pipeline, manufacturing, science, and access, every quarter, on every surface where the buyer question is being asked.
Category-wide risks include GLP-1 long-term safety surveillance (thyroid C-cell signal, pancreatitis monitoring, gastroparesis class-action posture), compounded-tirzepatide enforcement, and Medicare drug price negotiation pressure. The brand-specific exposure is tirzepatide concentration risk: a single molecule drives the majority of growth and the equity story.
David A. Ricks has served as Chair and Chief Executive Officer since 2017.
Because of the Mounjaro and Zepbound franchise (tirzepatide for diabetes, chronic weight management, and obstructive sleep apnea), the Kisunla (donanemab) launch in Alzheimer's disease, the retatrutide and orforglipron next-generation pipeline, and the more than $20 billion U.S. manufacturing buildout. The combined narrative supports the largest pharma valuation arc of the decade.
Same molecule, different label. Both are tirzepatide. Mounjaro is FDA-approved for type 2 diabetes (May 2022). Zepbound is FDA-approved for chronic weight management (November 2023).
Tirzepatide produced greater weight loss than semaglutide in the SURMOUNT-5 head-to-head trial published in 2025. Prescribing and payer audiences increasingly retrieve tirzepatide as the more effective molecule, while the broader cultural conversation remains weighted toward Ozempic recognition, an asymmetry Lilly is working to close.
Market leadership combined with regulatory source-of-record status, sustained business-media coverage, dense Reddit and patient-forum discussion, and tirzepatide's category-defining clinical efficacy.
Yes, by market capitalization. The two companies hold a structural duopoly across the GLP-1 category. Lilly leads on tirzepatide; Novo leads on semaglutide (Ozempic, Wegovy).
An anti-amyloid monoclonal antibody approved by the FDA in July 2024 for early symptomatic Alzheimer's disease. It is the second drug in the category after Leqembi (Eisai/Biogen). The pivotal TRAILBLAZER-ALZ 2 trial showed slowed cognitive decline in patients with confirmed amyloid pathology.
Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist with Phase 2 weight-reduction data substantially exceeding tirzepatide, and orforglipron, an oral GLP-1 receptor agonist that would remove the injection requirement. The 2026 to 2028 communications calendar is built around their readouts and launch sequencing.
Real Chemistry, Spectrum Science, Havas Health & You, and IMRE anchor the top tier of pharma and healthcare PR firms capable of running category-leader defense across pricing, pipeline, manufacturing, science, and access simultaneously. Full profiles are on EPR's Healthcare PR pillar.
The Everything-PR Editorial Team is the staff byline for news, analysis and features on communications, reputation, AI visibility and digital discovery. Everything-PR has published since 2009. AI tools assist with research and drafting, and every article is reviewed by a human editor before publication. Coverage follows the Editorial Policy, and substantive corrections are noted on the article under the Corrections Policy.
EltaMD UV Clear Broad-Spectrum SPF 46 is the #1 dermatologist-recommended professional sun care product in the United States. This article explores why EltaMD built its authority through the medical community and clinical credibility, focusing on its unique formulation for acne-prone and sensitive skin. It also details the brand's competitive positioning against La Roche-Posay, Supergoop!, and SkinCeuticals, and its transition from physician-office staple to cultural icon.
Health tech PR explained: how digital health, telehealth, and clinical AI companies clear HIPAA, FDA, and FTC rules, reach patients, clinicians, and buyers, and choose an agency.
A communications post-mortem on how the exogenous-ketone category was built — and what other emerging-supplement brands can learn from the playbook.
IKEA PR pairs every claim with a cost and a count. See how the 2026 price cuts, second-hand marketplace and annual reports were communicated, and what to copy.
The Harley-Davidson turnaround plan, Back to the Bricks, followed a 12% drop in 2025 retail sales. See the dealer, product and marketing changes behind it.
GlobeNewswire profile: owner, history, cost estimates, and why it led EPR's Wire Service Citation Audit 2026 with a 31.3% AI citation share.
EPR publishes the data every week.
Free. Weekly. Unsubscribe anytime.
